Drug Profile
Cilastatin/imipenem/relebactam - Merck Sharp and Dohme
Alternative Names: Cilastatin/relebactam/imipenem; IMI/REL; Imipenem/cilastatin/relebactam; Imipenem/relebactam/cilastatin; MK-7655A; RECARBRIO; Relebactam + imepenem/cilastatin; Relebactam/cilastatin/imipenem; Relebactam/imipenem/cilastatinLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Merck Sharp & Dohme
- Class Anti-infectives; Antibacterials; Azabicyclo compounds; Carbapenems; Cyclopropanes; Piperidines; Small molecules; Thienamycins
- Mechanism of Action Beta lactamase inhibitors; Cell wall inhibitors; Exopeptidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Intra-abdominal infections; Nosocomial pneumonia; Urinary tract infections; Ventilator associated pneumonia
- Registered Bacteraemia; Bacterial infections
- Phase II/III Gram-negative infections
- No development reported Sepsis
Most Recent Events
- 11 Oct 2023 Efficacy and adverse events data from a phase III trial in Nosocomial pneumonia and Ventilator-associated-pneumonia presented at the IDWeek 2023 (IDW-2023)
- 28 Sep 2023 No recent reports of development identified for phase-I development in Gram-negative-infections(In adolescents, In children, In infants, In neonates) in Bulgaria (IV, Infusion)
- 28 Sep 2023 No recent reports of development identified for phase-I development in Gram-negative-infections(In adolescents, In children, In infants, In neonates) in Greece (IV, Infusion)